Orexin A (human, rat, mouse) (acetate)
(Synonyms: Hypocretin-1 (human, rat, mouse) (acetate)) 目录号 : GC67957Orexin A (Hypocretin-1) (human, rat, mouse) acetate 是一种具有镇痛特性的下丘脑神经肽 (可透过血脑屏障)。Orexin A (human, rat, mouse) acetate 也是一种 OX1R 激动剂，能以时间和剂量依赖性的方式诱导 SH-SY5Y 细胞 BDNF 和 TH 蛋白的表达。Orexin A (human, rat, mouse) acetate 可用于食欲调节、神经退行性疾病，以及调节伤害性信息传递的研究。
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Orexin A (Hypocretin-1) (human, rat, mouse) acetate is a hypothalamic neuropeptide with analgesic properties (crosses the blood-brain barrier). Orexin A (human, rat, mouse) acetate is also an OX1R agonist that induces the expression of BDNF and TH proteins in SH-SY5Y cells in a time- and dose-dependent manner. Orexin A (human, rat, mouse) acetate can be used in studies of appetite regulation, neurodegenerative diseases and modulation of injurious messaging[1][2][3].
Orexin A (human, rat, mouse) acetate (0.1, 1, 10, 100 nM; 24 h) increases the expression of BDNF in SH-SY5Y human dopaminergic neuroblastoma cells in a dose-dependent manner[1].
Orexin A (human, rat, mouse) acetate (1 nM; 1, 3, 6, 12, 24 h) increases the expression of BDNF, TH, and PI3K in a time-dependent manner in SH-SY5Y cells[1].
Western Blot Analysis[1]
| Cell Line: | SH-SY5Y cells |
| Concentration: | 0.1, 1, 10, 100 nM |
| Incubation Time: | 24 h |
| Result: | Increased the expression of PI3K and TH in a dose-dependent manner. Significantly induced BDNF expression at the dose of 1 and 10 nM. |
Western Blot Analysis[1]
| Cell Line: | SH-SY5Y cells |
| Concentration: | 1 nM |
| Incubation Time: | 1, 3, 6, 12, 24 h |
| Result: | Showed the expression of PI3K rapidly increased by 72.6 % as soon as 3 h, which maintained at high levels in the following 24 h. Increased the protein level of BDNF and the increased rate was 44.8%, and the protein level of TH significantly increased at 12 h by 48.5%. |
Orexin A (human, rat, mouse) acetate (300 ng/mouse; i.c.v.; single daily for 8 days) attenuates the loss of dopaminergic neurons and the decrease of tyrosine hydroxylase (TH) expression in the substantia nigra, normalized the striatal dopaminergic fibers, and prevents the depletion of dopamine and its metabolites in the striatum[1].
Orexin A (human, rat, mouse) acetate (10, 30 mg/kg; i.v.; single) shows to be analgesic in the carrageenan-induced thermal hyperalgesia model and PPQ-induced mouse abdominal constriction model[2].
| Animal Model: | Male C57BL/6 mice (10-week-old; 22-26 g; MPTP-Induced Mouse Model of PD)[1]. |
| Dosage: | 300 ng/mouse |
| Administration: | Intracerebroventricular injection; single daily for 8 days |
| Result: | Reversed MPTP-induced motor impairments via OX1R and increased the protein expression of BDNF in nigral dopaminergic neurons. Improved MPTP-induced impairments in spatial Learning and memory and protected dopaminergic neurons against MPTP-induced neurotoxicity. Attenuated the reduction of dopaminergic neurons in the substantia nigra and restored the reduction of dopaminergic fibers in the striatum. |
| Animal Model: | Female ICR mice (17-28 g; carrageenan-induced thermal hyperalgesia model)[2]. |
| Dosage: | 10, 30 mg/kg |
| Administration: | Intravenous injection; single; 5 min pre-test |
| Result: | Increased paw withdrawal latency to the thermal stimulus back to baseline levels. |
| Animal Model: | Male ICR mice (17-20 g; phenyl-p-quinone (PPQ)-induced mouse abdominal constriction model)[2]. |
| Dosage: | 3, 10, 30 mg/kg |
| Administration: | Intravenous injection; single; given immediately before PPQ |
| Result: | Increased the latency to the first PPQ-induced constriction from 357.4 s (blank control group) to 500.3 s at 10 mg/kg and 594.5 s at 30 mg/kg. |
[1]. Liu MF, et al. Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease. Front Neurosci. 2018 Nov 15;12:835.
[2]. Bingham S, et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain. 2001 May;92(1-2):81-90.
[3]. Rodgers RJ, et al. Orexins and appetite regulation. Neuropeptides. 2002 Oct;36(5):303-25.
| Cas No. | SDF | Download SDF | |
| 别名 | Hypocretin-1 (human, rat, mouse) (acetate) | ||
| 分子式 | C154H247N47O46S4 | 分子量 | 3621.15 |
| 溶解度 | H2O : ≥ 50 mg/mL (13.81 mM) | 储存条件 | Store at -20°C, protect from light, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2762 mL | 1.3808 mL | 2.7616 mL |
| 5 mM | 0.0552 mL | 0.2762 mL | 0.5523 mL |
| 10 mM | 0.0276 mL | 0.1381 mL | 0.2762 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。